Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05914961
Other study ID # ICK-Breast
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date June 2024
Est. completion date April 2035

Study information

Verified date January 2024
Source University Hospital Tuebingen
Contact Tobias Engler, Dr.
Phone 07071 29 82211
Email Tobias.Engler@med.uni-tuebingen.de
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

ICK-breast is a prospective, multicentric, non-interventional investigator-initiated trial (IIT) that aims to investigate the prognostic value of CRP kinetics in early and advanced or metastatic triple negative breast cancer (TNBC) under immune checkpoint inhibitor (ICI) therapy on pathological complete response (pCR) and event-free survival in early TNBC patients, and objective response rate (ORR), progression-free survival (PFS) and overall survival (OS) in advanced or metastatic TNBC.


Description:

Immunotherapy, which involves activating the body's immune system for cancer treatment, has already been widely incorporated into the standard care of breast cancer patients with early and metastatic triple-negative breast cancer (TNBC). This study aims to investigate how inflammatory markers such as C-reactive protein (CRP) change during and after immunotherapy. Study findings from other tumor types (kidney, lung, bladder) suggest that immunotherapy is particularly effective when a mild inflammatory response is triggered in the body. The investigators want to examine this using CRP measurement. CRP measurement can easily be integrated into clinical routine as it only requires a blood sample. And since the patients already need a blood draw for chemotherapy, CRP measurement can be performed directly from the blood sample. The goal of this prospective study is to determine whether changes in CRP levels in the blood can predict the disease progression or response to immunotherapy.


Recruitment information / eligibility

Status Recruiting
Enrollment 225
Est. completion date April 2035
Est. primary completion date April 2025
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria: - women = 18 years of age - histologically proven early or advanced or metastatic invasive breast cancer irrespective of therapy line - ER-negative and progesterone receptor (PR)-negative and human epidermal growth factor receptor 2 (HER2)-negative (IHC 0-2+, Fluorescence In Situ Hybridization (FISH) neg.) - patients with advanced or metastatic disease must be programmed cell death ligand 1 (PD-L1)-positive (IC = 1 or combined positive score (CPS) = 10) in the experimental group - planned ICI therapy in combination with chemotherapy in the experimental group - written informed consent into ICK-breast Exclusion Criteria: - ER-positive or PR-positive - HER2-positive (IHC 2+, FISH pos or IHC 3+) - any systemic breast cancer therapy before inclusion into the trial for early breast cancer patients - any ICI therapy before inclusion into the trial - pregnant or lactating patients - inadequate general condition (not fit for chemotherapy)

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
Germany Department of Women's Health Tuebingen

Sponsors (3)

Lead Sponsor Collaborator
University Hospital Tuebingen University Hospital Freiburg, University Hospital Ulm

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Primary Prognostic value of CRP kinetics under ICI therapy on pathologic complete response (PCR) Evaluation of CRP kinetics to predict pCR in early (pathologic complete response) TNBC treated with ICI in combination with chemotherapy. The CRP value is determined from blood samples. duration of therapy and follow-up data (10 years)
Secondary Prognostic value of CRP kinetics under ICI therapy on objective response rate (ORR), progression free survival (PFS), event-free survival (EFS), invasive recurrence free survival and overall survival (OS) evaluation of CRP kinetics to predict objective response in patients with metastatic TNBC receiving ICI in combination with chemotherapy
evaluation of CRP kinetics to predict progression free survival in patients with metastatic TNBC receiving ICI in combination with chemotherapy
evaluation of CRP kinetics to predict overall survival in patients with metastatic TNBC receiving ICI in combination with chemotherapy
evaluation of CRP kinetics to predict event-free survival in patients with early TNBC receiving ICI in combination with chemotherapy
evaluation of CRP kinetics to predict distant invasive recurrence free survival in patients with early TNBC receiving ICI in combination with chemotherapy The CRP value is determined from blood samples.
duration of therapy and follow-up data (10 years)
See also
  Status Clinical Trial Phase
Not yet recruiting NCT05491694 - To Evaluate the Efficacy of Toripalimab Combined With Chemotherapy After HIFU Induction in the Treatment of Early Triple-negative Breast Cancer Phase 2
Recruiting NCT06125080 - The Efficacy and Safety of Utidelone Plus Tirelizumab and Bevacizumab for Advanced or Metastatic Triple-negative Breast Cancer (UTILIZABLE) :Single-arm, Prospective, Open Clinical Study Phase 2
Recruiting NCT05396612 - Role of the Immune Environment in Response to Therapy in Breast Cancer
Completed NCT03719326 - A Study to Evaluate Safety/Tolerability of Immunotherapy Combinations in Participants With Triple-Negative Breast Cancer or Gynecologic Malignancies Phase 1
Recruiting NCT04674306 - Adjuvant Therapy With an Alpha-lactalbumin Vaccine in Triple-Negative Breast Cancer Early Phase 1
Recruiting NCT06230185 - ctDNA Based MRD Testing for NAC Monitoring in TNBC
Recruiting NCT05491226 - Reinvigorating TNBC Response to Immunotherapy With Combination Myeloid Inhibition and Radiation Phase 2
Withdrawn NCT05062174 - Breast Cancer BRCA1 Carriers: a Pilot Study
Recruiting NCT06059469 - PSMA-PET/CT to Assess the Expression of Specific Membrane Antigen (PSMA) in Patients With Progressive Triple-negative Breast Cancer. Phase 2
Terminated NCT03875313 - Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors Phase 1/Phase 2
Completed NCT03057600 - Study of CB-839 in Combination w/ Paclitaxel in Participants of African Ancestry and Non-African Ancestry With Advanced Triple Negative Breast Cancer (TNBC) Phase 2
Recruiting NCT04706962 - TH1902 in Patients With Advanced Solid Tumors Phase 1
Recruiting NCT05274451 - A Study to Investigate LYL797 in Adults With Solid Tumors Phase 1
Not yet recruiting NCT04755868 - Talazoparib Maintenance Therapy in Triple-negative Breast Cancer Phase 2
Recruiting NCT01042379 - I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer Phase 2
Recruiting NCT05848739 - A Phase 1-2 of ST316 With Selected Advanced Unresectable and Metastatic Solid Tumors Phase 1
Not yet recruiting NCT06358573 - Intratumoral INT230-6 Followed by Neoadjuvant Immuno-chemotherapy in Patients With Early TNBC. INVINCIBLE-4-SAKK Phase 2
Active, not recruiting NCT05451849 - A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer Phase 1/Phase 2
Completed NCT05390710 - PhI to Solid Tumors and PhII to Locally Advanced or mTNBC Phase 1
Recruiting NCT06387628 - LM-108 in Combination With PD-1 Based Treatment for Patients With Recurrent or Metastatic Triple - Negative Breast Cancer Phase 2